Inactive Instrument

MYOS Corp Stock OTC Bulletin Board

Equities

US5540511020

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for MYOS Corp
Sales 2021 22.13M 30.26M Sales 2022 43.11M 58.95M Capitalization 24M 32.82M
Net income 2021 -43M -58.8M Net income 2022 -47M -64.27M EV / Sales 2021 1.74 x
Net cash position 2021 7.44M 10.18M Net cash position 2022 4.37M 5.97M EV / Sales 2022 0.46 x
P/E ratio 2021
-1.04 x
P/E ratio 2022
-0.41 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Sector
-
More about the company